- HBV Mutations During Antiviral Therapy in Patients with Chronic Hepatits B
-
Hwang SG
- KMID: 1119357
- Korean J Hepatol.
- 2005 Dec;11(4):311-319.
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Monitoring and Treatment Strategy for Chronic Hepatitis B and Antiviral Resistant Hepatitis B
-
Kim TY, Sohn JH
- KMID: 782870
- Korean J Gastroenterol.
- 2007 Jun;49(6):346-355.
Clinical management of chronic hepatitis B is rapidly evolving after the recent development of new antiviral drugs. These agents have been shown to be effective in improving virological, biochemical, and... -
- CITED
-
- Close
- SHARE
-
- Close
- Relationship Between Core Gene Mutations of Hepatitis B Virus and Response to Alpha Interferon Therapy in Chronic Hepatitis B
-
Yoo BC, Kim HJ, Do JH, Park SM
- KMID: 863113
- Korean J Hepatol.
- 2002 Dec;8(4):381-388.
BACKGROUND/AIMS: Treatment of chronic hepatitis B with interferon results in a sustained loss of hepatitis B virus DNA and hepatitis B e antigen (HBeAg) and remission of liver disease... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B
-
Kim JH, Moon HW, Ko SY, Choe WH, Kwon SY
- KMID: 2069764
- Clin Mol Hepatol.
- 2014 Sep;20(3):274-282.
- doi: 10.3350/cmh.2014.20.3.274
BACKGROUND/AIMS: Quantitation of hepatitis B surface antigen (HBsAg) is an increasingly popular method to determine the treatment response in chronic hepatitis B (CHB) patients. The clinical value of HBsAg level... -
- CITED
-
- Close
- SHARE
-
- Close
- The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
-
Kim JH, Ahn SH, Ko SY, Choe WH, Kim KH, Kwon SY
- KMID: 2373120
- Clin Mol Hepatol.
- 2016 Jun;22(2):241-249.
- doi: 10.3350/cmh.2015.0053
BACKGROUND/AIMS: Before tenofovir (TDF) become available in South Korea, combination therapy with entecavir (ETV) and adefovir (ADV) was the most potent regimen for chronic hepatitis B (CHB) patients who fail... -
- CITED
-
- Close
- SHARE
-
- Close
- Predictive Factors and Efficacy of Lamivudine Treatment in Chronic Hepatitis B Infection
-
Park NH, Shin JW, Park JH, Bang SJ, Kim DH, Joo KR, Kim DH
- KMID: 772561
- Korean J Gastroenterol.
- 2003 Oct;42(4):303-312.
BACKGROUND/AIMS: Lamivudine, an oral nucleoside analogue, effectively suppresses hepatitis B virus (HBV) replications and improves liver enzymes as well as liver histology. The aim of this study was to evaluate... -
- CITED
-
- Close
- SHARE
-
- Close
- Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients
-
Hwang JA, Kim KB, Yang MJ, Lim SG, Hwang JC, Cheong JY, Cho SW, Kim SS
- KMID: 2164363
- Clin Mol Hepatol.
- 2015 Jun;21(2):131-140.
- doi: 10.3350/cmh.2015.21.2.131
BACKGROUND/AIMS: To determine the efficacies of entecavir (ETV) in nucleos(t)ide analogue (NA)-naive chronic hepatitis B (CHB) patients and in those with prior lamivudine (LAM) use who did not develop resistance. METHODS:... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of Initial Virologic Response to Adefovir on the Development of Resistance to Adefovir in Lamivudine-resistant Chronic Hepatitis B
-
Kim IH, Kim SH, Kim HC, Shin KD, Kim SW, Lee SO, Lee ST, Kim DG
- KMID: 760736
- Korean J Hepatol.
- 2007 Sep;13(3):349-362.
- doi: 10.3350/kjhep.2007.13.3.349
BACKGROUND/AIMS: Adefovir dipivoxil (ADV) resistance in patients with lamivudine-resistant chronic hepatitis B is not well understood. This study examined the initial virologic response (IVR) to ADV, the rate of... -
- CITED
-
- Close
- SHARE
-
- Close
- Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
-
Kim JH, Ko SY, Choe WH, Kwon SY, Lee CH
- KMID: 1705205
- Clin Mol Hepatol.
- 2013 Sep;19(3):273-279.
- doi: 10.3350/cmh.2013.19.3.273
BACKGROUND/AIMS: Lamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB). The aim of this study was to... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir
-
Ze E, Baek EK, Lee JJ, Chung HW, Ahn DG, Cho HJ, Kwon JC, Kim HJ, Lee H
- KMID: 2069763
- Clin Mol Hepatol.
- 2014 Sep;20(3):267-273.
- doi: 10.3350/cmh.2014.20.3.267
BACKGROUND/AIMS: Adefovir (ADV) and lamivudine (LAM) combination therapy (ADV+LAM) has been a useful option for patients with LAM-resistant (LAM-r) chronic hepatitis B (CHB). However, the long-term outcomes of LAM+ADV and... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Tenofovir-based Rescue Therapy for Patients with Drug-resistant Chronic Hepatitis B
-
Choi K, Lee HM, Jun BG, Lee SH, Kim HS, Kim SG, Kim YS, Kim BS, Jeong SW, Jang JY, Kim YD, Cheon GJ
- KMID: 2373178
- Korean J Gastroenterol.
- 2015 Jan;65(1):35-42.
- doi: 10.4166/kjg.2015.65.1.35
BACKGROUND/AIMS: Tenofovir disoproxil fumarate (TDF) plays a pivotal role in the management of drug-resistant chronic hepatitis B. However, it remains unclear whether TDF-nucleoside analogue combination therapy provides better outcomes than... -
- CITED
-
- Close
- SHARE
-
- Close
- Long-Term Outcomes and Dynamics of Mutants Associated with Lamivudine-Adefovir Rescue Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B
-
Kim J, Lee SH, Kim HS, Choi K, Jeong SW, Kim SG, Jang JY, Kim YS, Kim BS
- KMID: 2380789
- Gut Liver.
- 2015 Jan;9(1):103-108.
- doi: 10.5009/gnl14018
BACKGROUND/AIMS: To investigate the association between the baseline profiles and dynamics of hepatitis B virus (HBV) DNA polymerase gene mutations and the long-term virological response of lamivudine (LAM)-adefovir (ADV) combination... -
- CITED
-
- Close
- SHARE
-
- Close
- Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
-
Park JG, Park SY
- KMID: 2351024
- Clin Mol Hepatol.
- 2015 Sep;21(3):242-248.
- doi: 10.3350/cmh.2015.21.3.242
BACKGROUND/AIMS: We compared the efficacies of entecavir (ETV) plus tenofovir (TDF) and ETV plus adefovir (ADV) in chronic hepatitis B (CHB) patients with genotypic resistance to lamivudine (LAM) who showed... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Lamivudine in Patients with Hepatitis B e Antigen-Negative Chronic Liver Diseases
-
Jeong ID, Park NH, Kim BC, Park JH, Seo KW, Kim DH, Joo KR, Kim DH
- KMID: 863140
- Korean J Hepatol.
- 2003 Jun;9(2):69-78.
BACKGROUND/AIMS: Lamivudine therapy is effective in inhibiting HBV replications in patients with HBeAg-negative chronic liver disease. However, the sustained response rate appears to be particularly poor, because the vast... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Outcomes after Discontinuation of Lamivudine in Chronic Hepatitis B Patients with Lamivudine Resistant HBV Mutant
-
Kim JK, Hwang SG, Park H, Choi HY, Cho HJ, Ko KH, Hong SP, Park PW, Kim NK, Rim KS
- KMID: 760605
- Korean J Hepatol.
- 2005 Sep;11(3):227-242.
BACKGROUND/AIMS: The therapeutic strategies of applying adefovir for treating lamivudine resistant HBV mutants are controversial. Thus, we observed the clinical outcomes after discontinuation of lamivudine to establish the timing... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical and Virologic Characteristics of Lamivudine Resistance in HBV-associated Chronic Liver Disease
-
Kim SS, Chung MG, Ju KT, Park DK, Kwon OS, Koo YS, Kim YK, Choi DJ, Hwang YJ, Kim JH
- KMID: 863116
- Korean J Hepatol.
- 2002 Dec;8(4):405-417.
BACKGROUND/AIMS: Lamivudine therapy in chronic hepatitis B has been shown to be effective in inhibiting HBV replication. However, lamivudine resistance has been developed with prolonged use. We studied to... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis B core antigen expression pattern predicts response to lamivudine therapy in patients with chronic hepatitis B
-
Shi KD, Hwang SG, Choi JH, Hwang IJ, Yoon JH, Kim KI, Kwon CI, Hong SP, Park PW, Rim KS
- KMID: 760784
- Korean J Hepatol.
- 2008 Jun;14(2):197-205.
- doi: 10.3350/kjhep.2008.14.2.197
BACKGROUNDS/AIMS: Negative hepatitis B core antigen (HBcAg) staining in hepatocytes is indicative of viral replication by an active immune response. HBcAg is expressed mainly in the cytoplasm in patients... -
- CITED
-
- Close
- SHARE
-
- Close
- Adequacy of Immediate Lamivudine Trial for Chronic Hepatitis B Patients with Acute Exacerbation
-
Lee CK, Suh JH, Cho YS, Won SY, Park IS
- KMID: 760528
- Korean J Hepatol.
- 2004 Mar;10(1):22-30.
BACKGROUND/AIMS: It has been unclear whether immediate antiviral therapy or observation under the expectation of spontaneous inactivation of hepatitis B virus (HBV), is more appropriate for the treatment of... -
- CITED
-
- Close
- SHARE
-
- Close
- Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients
-
Cho JH, Cheong JY, Kang JK, Park JS, Lee MH, Lim NK, Hong SP, Kim SO, Yoo WD, Cho SW
- KMID: 1073330
- Korean J Hepatol.
- 2008 Mar;14(1):58-66.
- doi: 10.3350/kjhep.2008.14.1.58
BACKGROUND/AIMS: Adefovir dipivoxil (adefovir) effectively inhibits both wild-type and lamivudine-resistant hepatitis B virus (HBV) replication. The development of adefovir resistance is both delayed and infrequent compared with lamivudine resistance.... -
- CITED
-
- Close
- SHARE
-
- Close
- Genotypic resistance to entecavir in chronic hepatitis B patients
-
Kim BU, Goo JC, Park BC, Kim SO, Hong SP, Jeong JI, Chae HB, Park SM, Youn SJ
- KMID: 1792593
- Korean J Hepatol.
- 2010 Jun;16(2):147-157.
- doi: 10.3350/kjhep.2010.16.2.147
BACKGROUND/AIMS: The prevalence and clinical characteristics of entecavir (ETV) resistance is not well known. The aim of this study was to determine the frequency of genotypic resistance in nonresponders and... -
- CITED
-
- Close
- SHARE
-
- Close
